Hypoallergenic ovalbumin as well as preparation method and application thereof

By mixing egg albumin with phosphate buffer and malt triose, and using gamma ray irradiation to destroy its structure, the problem of reducing egg sensitivity in the prior art is solved, and hyposensitivity suitable for industrial production is achieved Preparation of ovalbumin.

CN118901863APending Publication Date: 2024-11-08AGRI INST OF AGRI JIANGXI PROVINCE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411082148.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art cannot effectively reduce the sensitization of eggs, resulting in an allergic reaction in people with egg allergies, and these methods are not suitable for industrial production.

Method used

The ovalbumin is mixed with phosphate buffer and treated under 250-300Mpa, then mixed with malt triose and freeze-dried, and then irradiated with gamma rays to destroy the structure and conformation of the ovalbumin and reduce its sensitization.

Benefits of technology

It has achieved a significant reduction in the sensitization of ovalbumin in a short period of time, and is suitable for industrial production, and provides hypoallergenic ovalbumin for the preparation of hypoallergenic health products.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of functional food preparation, in particular to low-sensitization ovalbumin as well as a preparation method and application thereof. The preparation method for reducing the allergenicity of the ovalbumin comprises the following steps: (1) mixing the ovalbumin with a phosphate buffer solution, and treating for 5-10 minutes under the condition of 250-300Mpa to obtain a treated ovalbumin solution; (2) mixing maltotriose with the ovalbumin solution treated in the step (1) to obtain a mixture; freeze-drying the mixture to obtain freeze-dried powder; (3) irradiating the freeze-dried powder by using gamma rays to obtain low-sensitization ovalbumin; and a radioactive source of the gamma rays is Co-60. By utilizing the preparation method disclosed by the invention, the low-sensitization ovalbumin can be obtained in a short time, and a basis is provided for industrial production of low-sensitization protein products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of functional food preparation, and in particular to a low-allergenic egg white protein and a preparation method and application thereof. Background Art

[0002] Eggs are very important raw materials in the food industry and an important food source for humans. Eggs can provide nutrients such as protein that the human body needs. The protein in eggs is easily digested and absorbed by the human body. However, eggs are prone to cause allergies in the human body. The best way to control egg allergies is to stay away from eggs or foods containing eggs. Therefore, eggs, an important nutritional supplement, are missing.

[0003] Ovalbumin is the protein with the highest content in eggs, accounting for 54% of the total protein in egg white, and is also the main cause of egg allergy. The existing technology has concluded through the study of ovalbumin IgG and IgE binding sites that the allergenic epitopes of ovalbumin are distributed throughout the amino acid sequence and spatial conformation.

[0004] Heat treatment, microwave, high pressure, irradiation, glycosylation modification, etc. are used to reduce the allergenicity of protein, providing a basis for low-allergenic egg products. These methods in the prior art are all used alone to reduce the allergenicity of eggs. Such methods alone cannot reduce the allergenicity of egg protein to a great extent, and still cause allergic reactions in people with egg allergies. In addition, the above methods take a long time and are not suitable for industrial production.

[0005] Therefore, there is an urgent need for a method that is rapid and can greatly reduce the allergenicity of eggs to meet the deficiencies of the existing technology. Summary of the invention

[0006] The purpose of the present invention is to provide a method suitable for industrial production and capable of greatly reducing the allergenicity of eggs, and in particular to a low-allergenic egg white protein and a preparation method and application thereof.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The present invention provides a preparation method for reducing the allergenicity of ovalbumin, comprising the following steps:

[0009] (1) mixing ovalbumin with phosphate buffer and treating at 250-300 MPa for 5-10 min to obtain a treated ovalbumin solution;

[0010] (2) mixing maltotriose with the ovalbumin solution treated in step (1) to obtain a mixture; freeze-drying the mixture to obtain a lyophilized powder;

[0011] (3) irradiating the freeze-dried powder with gamma rays to obtain hypoallergenic ovalbumin;

[0012] The radiation source of the gamma ray is Co-60.

[0013] Preferably, the mass volume ratio of the ovalbumin and phosphate buffer mixed in step (1) is 1-3 mg: 1-3 mL;

[0014] The initial concentration of the phosphate buffer is 0.03-0.06 mol / L.

[0015] Preferably, the mass volume ratio of the maltotriose mixed with the treated ovalbumin solution in step (2) is 1 mg: 0.5-0.8 mL.

[0016] Preferably, the irradiation dose is 15 to 30 kGy.

[0017] The present invention also provides low-allergenic ovalbumin obtained by the preparation method.

[0018] The present invention also provides the use of the low-allergenic ovalbumin obtained by the preparation method in the preparation of low-allergenic health-care products.

[0019] The present invention also provides the use of the hypoallergenic ovalbumin in the preparation of hypoallergenic health care products.

[0020] The present invention provides a low-allergenic ovalbumin and a preparation method and application thereof. The method of the present invention comprises: (1) mixing ovalbumin with a phosphate buffer solution, treating it at 250-300 MPa for 5-10 min to obtain a treated ovalbumin solution; (2) mixing maltotriose with the treated ovalbumin solution of step (1) to obtain a mixture; freeze-drying the mixture to obtain a freeze-dried powder; (3) irradiating the freeze-dried powder with gamma rays to obtain low-allergenic ovalbumin; the radiation source of the gamma rays is Co-60. The present invention utilizes high pressure to treat ovalbumin in order to destroy the structure and conformation of ovalbumin, thereby reducing its allergenicity; and utilizes maltotriose for glycosylation to change the structure of ovalbumin and improve its functional activity; after irradiation with the rays, the surface of the ovalbumin is smooth and has voids.

[0021] The preparation method of the present invention can be used to obtain low-allergenic egg white protein in a short time, providing a basis for the industrial production of low-allergenic protein products. DETAILED DESCRIPTION

[0022] The present invention provides a preparation method for reducing the allergenicity of ovalbumin, comprising the following steps:

[0023] (1) mixing ovalbumin with phosphate buffer and treating at 250-300 MPa for 5-10 min to obtain a treated ovalbumin solution;

[0024] (2) mixing maltotriose with the ovalbumin solution treated in step (1) to obtain a mixture; freeze-drying the mixture to obtain a lyophilized powder;

[0025] (3) irradiating the freeze-dried powder with gamma rays to obtain hypoallergenic ovalbumin;

[0026] The radiation source of the gamma ray is Co-60.

[0027] In the present invention, the egg white protein is egg white protein of chicken egg, and the preparation method of the egg white protein of chicken egg is: using an egg separator to separate the egg white and egg yolk of the egg. Take the egg white, mix the egg white with the sodium chloride solution in a volume ratio of 1:2-5, stir for 2-5 hours, obtain an intermediate solution, adjust the pH of the intermediate solution to 6.0, add PGE-8000 surfactant thereto, stir magnetically for 2 hours, centrifuge for 10 minutes at 4°C and 15000rpm, collect the supernatant, dialyze the supernatant with deionized water for 3-5 times, freeze-dry, and obtain the egg white protein. The volume ratio of the egg white and the sodium chloride solution is preferably 1:4; the initial concentration of the sodium chloride solution is 40-60mmol / L, preferably 50mmol / L; the added volume of the PGE-8000 surfactant is 20-40% of the volume of the intermediate solution; the number of times the supernatant is dialyzed is preferably 4 times.

[0028] In the present invention, the mass volume ratio of the egg white protein and the phosphate buffer in step (1) is 1-3 mg: 1-3 mL, preferably 1 mg: 1 mL; the initial concentration of the phosphate buffer is 0.03-0.06 mol / L, preferably 0.05 mol / L. In the present invention, the treatment pressure is preferably 300 MPa, and the treatment time is preferably 5 min;

[0029] In the present invention, the mass volume ratio of the maltotriose mixed with the treated ovalbumin solution in step (2) is 1 mg: 0.5-0.8 mL, preferably 1 mg: 0.6 mL. In the present invention, the freeze-drying method is: first freeze-drying at -40-50°C for 6-10 hours, then freeze-drying at -18-22°C for 6-10 hours. Preferably, freeze-drying at -45°C for 8 hours, then freeze-drying at -20°C for 8 hours.

[0030] In the present invention, the irradiation dose is 15-30 kGy, preferably 20 kGy. The irradiation dose of the present invention is within the edible range.

[0031] The present invention also provides low-allergenic ovalbumin obtained by the preparation method.

[0032] The present invention also provides the use of the low-allergenic ovalbumin obtained by the preparation method in the preparation of low-allergenic health-care products.

[0033] The present invention also provides the use of the hypoallergenic ovalbumin in the preparation of hypoallergenic health care products.

[0034] The solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be understood as limiting the protection scope of the present invention.

[0035] The egg white protein of the embodiment and the comparative example of the present invention is egg white protein, and the preparation method of the egg white protein is: using an egg separator to separate the egg white and the egg yolk of the egg. Take the egg white, mix the egg white with a 50mmol / L sodium chloride solution at a volume ratio of 1:3, stir for 3 hours, obtain an intermediate solution, adjust the pH of the intermediate solution to 6.0, add 30% of the volume of the intermediate solution PGE-8000 surfactant, stir magnetically for 2 hours, centrifuge at 4°C, 15000rpm for 10 minutes, collect the supernatant, dialyze the supernatant with deionized water 4 times, freeze-dry (first freeze-dry at -50°C for 10 hours, then freeze-dry at -20°C for 8 hours), and obtain the egg white protein.

[0036] Example 1

[0037] Mix 10 mg of ovalbumin with 10 mL of 0.05 mol / L phosphate buffer and treat at 300 MPa for 5 min to obtain a treated ovalbumin solution. Take 5 mL of the treated ovalbumin solution and add 10 mg of maltotriose to mix evenly to obtain a mixture. Place the mixture in a freeze dryer, freeze-dry at -40 ° C for 8 hours, and then freeze-dry at -22 ° C for 8 hours to obtain a freeze-dried powder. Irradiate the freeze-dried powder with gamma rays radiated by Co-60 at a dose of 15 kGy to obtain low-allergenic ovalbumin.

[0038] Example 2

[0039] Mix 10 mg of ovalbumin with 20 mL of 0.05 mol / L phosphate buffer and treat at 250 MPa for 8 min to obtain a treated ovalbumin solution. Take 8 mL of the treated ovalbumin solution and add 10 mg of maltotriose to mix evenly to obtain a mixture. Place the mixture in a freeze dryer, freeze-dry at -50 ° C for 6 h, and then freeze-dry at -20 ° C for 10 h to obtain a freeze-dried powder. Irradiate the freeze-dried powder with gamma rays radiated by Co-60 at a dose of 30 kGy to obtain low-allergenic ovalbumin.

[0040] Example 3

[0041] Mix 10 mg of ovalbumin with 10 mL of 0.05 mol / L phosphate buffer and treat at 280 MPa for 10 min to obtain a treated ovalbumin solution. Take 7 mL of the treated ovalbumin solution and add 10 mg of maltotriose to mix evenly to obtain a mixture. Place the mixture in a freeze dryer, freeze-dry at -45 ° C for 10 h, and then freeze-dry at -18 ° C for 6 h to obtain a freeze-dried powder. Irradiate the freeze-dried powder with gamma rays radiated by Co-60 at a dose of 20 kGy to obtain low-allergenic ovalbumin.

[0042] Comparative Example 1

[0043] Compared with the solution of Example 1, Comparative Example 1 does not perform high pressure treatment, and the specific solution is:

[0044] Ovalbumin, maltotriose and water were mixed in a mass ratio of 1:2:2 to obtain a mixture. The mixture was placed in a freeze dryer, first freeze-dried at -40°C for 8 hours, and then freeze-dried at -22°C for 8 hours to obtain a freeze-dried powder. The freeze-dried powder was irradiated with gamma rays radiated by Co-60 at a dose of 15 kGy to obtain low-allergenic ovalbumin.

[0045] Comparative Example 2

[0046] Compared with the scheme of Example 1, Comparative Example 2 does not perform saccharification treatment, and the specific scheme is:

[0047] 10 mg of ovalbumin was mixed evenly with 10 mL of 0.05 mol / L phosphate buffer and treated at 300 MPa for 5 min to obtain a treated ovalbumin solution. The treated ovalbumin was placed in a freeze dryer, first freeze-dried at -40 ° C for 8 h, and then freeze-dried at -22 ° C for 8 h to obtain a freeze-dried powder. The freeze-dried powder was irradiated with gamma rays radiated by Co-60 at a dose of 15 kGy to obtain low-allergenic ovalbumin.

[0048] Comparative Example 3

[0049] Compared with the solution of Example 1, Comparative Example 3 does not perform irradiation treatment, and the specific solution is:

[0050] 10 mg of ovalbumin was mixed with 10 mL of 0.05 mol / L phosphate buffer and treated at 300 MPa for 5 min to obtain a treated ovalbumin solution. 5 mL of the treated ovalbumin solution was added with 10 mg of maltotriose and mixed to obtain a mixture. The mixture was placed in a freeze dryer, first freeze-dried at -40 ° C for 8 h, and then freeze-dried at -22 ° C for 8 h to obtain low-allergenic ovalbumin.

[0051] Comparative Example 4

[0052] Compared with the solution of Example 1, Comparative Example 4 only performs high pressure treatment, specifically:

[0053] 10 mg of ovalbumin was mixed evenly with 10 mL of 0.05 mol / L phosphate buffer, treated at 300 MPa pressure for 5 min, placed in a freeze dryer, first freeze-dried at -40°C for 8 h, and then freeze-dried at -22°C for 8 h to obtain low-allergenic ovalbumin.

[0054] Comparative Example 5

[0055] Compared with the solution of Example 1, Comparative Example 5 only performs saccharification treatment, specifically:

[0056] Ovalbumin, maltotriose and water were mixed in a mass ratio of 1:2:2 to obtain a mixture, and the mixture was placed in a freeze dryer, first freeze-dried at -40°C for 8 hours, and then freeze-dried at -22°C for 8 hours to obtain low-allergenic ovalbumin.

[0057] Comparative Example 6

[0058] Compared with the solution of Example 1, Comparative Example 6 only performs irradiation treatment, specifically:

[0059] 10 mg of ovalbumin was irradiated with gamma rays radiated by Co-60 at a dose of 15 kGy to obtain ovalbumin with low allergenicity.

[0060] Comparative Example 7

[0061] Compared with Example 1, the drying method in the scheme of Comparative Example 7 is different from that in Example 1, specifically:

[0062] Mix 10 mg of ovalbumin with 10 mL of 0.05 mol / L phosphate buffer, and treat at 300 MPa for 5 min to obtain a treated ovalbumin solution. Take 5 mL of the treated ovalbumin solution and add 10 mg of maltotriose to mix evenly to obtain a mixture. Place the mixture in an oven at 50 ° C and dry for 48 hours to obtain a dried product. Irradiate the dried product with gamma rays radiated by Co-60 at a dose of 15 kGy to obtain low-allergenic ovalbumin.

[0063] Experimental Example 1

[0064] The free amino acid levels in the low-allergenic ovalbumin obtained in Examples 1 to 3 and Comparative Examples 1 to 7 were measured using the o-phthalaldehyde method, with the free amino acid levels in blank ovalbumin as a control. The test results are shown in Table 1.

[0065] Table 1 Free amino acid content in low-allergenic ovalbumin prepared by different methods

[0066] Group Free amino acid content / (mg / mL) Example 1 0.001±0.001 Example 2 0.000±0.001 Example 3 0.001±0.001 Comparative Example 1 0.023±0.004 Comparative Example 2 0.028±0.005 Comparative Example 3 0.030±0.003 Comparative Example 4 0.052±0.004 Comparative Example 5 0.048±0.005 Comparative Example 6 0.041±0.004 Comparative Example 7 0.019±0.003 Control group 0.063±0.006

[0067] Table 1 shows that the content of free amino acids in the low-allergenic ovalbumin obtained by the methods of Examples 1 to 3 is lower than that of Comparative Examples 1 to 7, and is substantially 0. This indicates that the method of the present invention can destroy the structure of ovalbumin to a great extent and reduce its allergenicity.

[0068] Experimental Example 2

[0069] 8-aniline-1-naphthalenesulfonic acid was used to measure the hydrophobicity of the surface of the low-allergenic ovalbumin in Examples 1 to 3 and Comparative Examples 1 to 7. Specifically:

[0070] Different low-allergenicity ovalbumin was prepared into solution samples of 0.1 mg / mL, 0.2 mg / mL, 0.4 mg / mL, 0.8 mg / mL, and 1.2 mg / mL. The solution samples of different concentrations were mixed with 8 mmol / L 8-aniline-1-naphthalenesulfonic acid solution at a volume ratio of 150:1. After reacting for 5 minutes under dark conditions, the fluorescence intensity of the solution samples of different concentrations was immediately measured. The emission wavelength during the measurement was 470 nm and the excitation wavelength was 390 nm. The hydrophobicity of the blank ovalbumin surface was used as a control. The slope formed by the fluorescence intensity and the solution sample concentration represents its surface hydrophobicity. The test results are shown in Table 2.

[0071] Table 2 Hydrophobicity of the surface of low-allergenic ovalbumin obtained by different methods

[0072] Group <![CDATA[Surface hydrophobicity (H0)]]> Example 1 1261.54±7.25 Example 2 1168.47±6.38 Example 3 1347.64±7.63 Comparative Example 1 853.67±4.16 Comparative Example 2 847.65±3.86 Comparative Example 3 817.64±3.28 Comparative Example 4 354.17±1.63 Comparative Example 5 452.68±2.17 Comparative Example 6 461.57±2.94 Comparative Example 7 942.36±4.88 Control group 217.86±1.68

[0073] Table 2 shows that the hydrophobicity of the surface of the hypoallergenic ovalbumin of Examples 1 to 3 is higher than that of Comparative Examples 1 to 7. This indicates that the protein structure in the hypoallergenic ovalbumin obtained by the method of the present invention is more damaged than that by other methods, thus increasing the probability of 8-aniline-1-naphthalenesulfonic acid binding to the hydrophobic region inside the molecule.

[0074] Experimental Example 3

[0075] The IgG binding capacity of different hypoallergenic ovalbumins was determined by enzyme-linked immunosorbent assay (ELISA).

[0076] The primary antibody used for IgG determination was rabbit anti-ovalbumin serum (purchased from Shanghai Yuanmu Biotechnology Co., Ltd.). 100 μL of 8 μg / mL ovalbumin solution was coated into the bottom of the ELISA plate, incubated at 37°C for 1 hour, washed with PBST, and 250 μL of 5% skim milk powder solution was added to each well, incubated at 37°C for 1 hour, washed with PBST and patted dry; then 100 μL of 150-fold diluted rabbit anti-ovalbumin serum and 1 μg / mL different low-sensitivity ovalbumin solutions (sample group) were added to each well, incubated at 37°C for 2 hours, washed with PBST and patted dry; 100 μL of 1:5000 dilution of goat anti-rabbit IgG horseradish peroxidase (purchased from Sigma, USA) was added to each well, incubated at 37°C for 1 hour; after washing with PBST, 100 μL of TMB color development solution was added to each well, and color was developed for 15 minutes in the dark at 37°C, and 100 μL of 2M sulfuric acid solution was added to each well to terminate the reaction. Measure OD 450 The IgG binding capacity was expressed as inhibition rate, and the results are shown in Table 3.

[0077] Inhibition rate % = (1-A / A0) × 100%;

[0078] A represents the absorbance value of the sample group;

[0079] A0 represents the absorbance value of the positive control group;

[0080] The positive control group used 150-fold diluted rabbit anti-ovalbumin serum instead of the sample.

[0081] Table 3 Binding capacity of low-allergenic ovalbumin prepared by different methods to IgG

[0082] Group Inhibition rate % Example 1 32 Example 2 29 Example 3 30 Comparative Example 1 54 Comparative Example 2 52 Comparative Example 3 49 Comparative Example 4 59 Comparative Example 5 63 Comparative Example 6 58 Comparative Example 7 46 Ovalbumin solution 65

[0083] Table 3 shows that the low-allergenicity ovalbumin obtained in Examples 1 to 3 has a lower ability to bind to IgG than that obtained in Comparative Examples 1 to 7. This is because the method of the present invention can change the structure of ovalbumin.

[0084] Experimental Example 4

[0085] According to the method of Experimental Example 3, the IgE binding capacity of different hypoallergenic ovalbumins was set.

[0086] The primary antibody used for IgE determination was serum from a patient with human egg allergy (purchased from Plasmalab, USA), and the dilution factor was 20. The secondary antibody was goat anti-human IgE horseradish peroxidase (purchased from Sigma, USA), and the dilution factor was 400. The positive control group was 20-fold diluted serum from a patient with human egg allergy instead of the sample.

[0087] The IgE binding capacity of different hypoallergenic ovalbumins was determined according to the method of Experimental Example 3, and the calculation formula was the same as that of Experimental Example 3. The results are shown in Table 4.

[0088] Table 4 Binding capacity of low-allergenic ovalbumin prepared by different methods to IgE

[0089] Group Inhibition rate % Example 1 28 Example 2 21 Example 3 26 Comparative Example 1 68 Comparative Example 2 54 Comparative Example 3 62 Comparative Example 4 69 Comparative Example 5 71 Comparative Example 6 68 Comparative Example 7 42 Ovalbumin solution 86

[0090] Table 4 shows that the low-allergenicity ovalbumin obtained in Examples 1 to 3 has a lower IgE-binding capacity than that obtained in Comparative Examples 1 to 7. This is because the method of the present invention can change the structure of ovalbumin.

[0091] As can be seen from the above embodiments, the present invention provides a low-allergenic ovalbumin and its preparation method and application. The method of the present invention comprises (1) mixing ovalbumin with phosphate buffer and treating it at 250-300Mpa for 5-10min to obtain a treated ovalbumin solution; (2) mixing maltotriose with the treated ovalbumin solution of step (1) to obtain a mixture; freeze-drying the mixture to obtain a lyophilized powder; (3) irradiating the lyophilized powder with gamma rays to obtain low-allergenic ovalbumin; the radiation source of the gamma rays is Co-60. The present invention uses high pressure to treat ovalbumin in order to destroy the structure and conformation of ovalbumin, thereby reducing its allergenicity; and uses maltotriose for glycosylation to change the structure of ovalbumin and improve its functional activity; after irradiation with rays, the surface of ovalbumin is smooth and has gaps, and its antioxidant activity is enhanced. The preparation method of the present invention can obtain low-allergenic ovalbumin in a short time, providing a basis for the industrial production of low-allergenic protein products.

[0092] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A preparation method for reducing the allergenicity of ovalbumin, characterized in that: The steps include: (1) mixing ovalbumin with phosphate buffer and treating at 250-300 MPa for 5-10 min to obtain a treated ovalbumin solution; (2) mixing maltotriose with the ovalbumin solution treated in step (1) to obtain a mixture; freeze-drying the mixture to obtain a lyophilized powder; (3) irradiating the freeze-dried powder with gamma rays to obtain hypoallergenic ovalbumin; The radiation source of the gamma ray is Co-60.

2. The preparation method according to claim 1, characterized in that: The ovalbumin and phosphate buffer solution in step (1) are mixed in a mass volume ratio of 1-3 mg:1-3 mL; The initial concentration of the phosphate buffer is 0.03-0.06 mol / L.

3. The preparation method according to claim 2, characterized in that: The mass volume ratio of the maltotriose mixed with the treated ovalbumin solution in step (2) is 1 mg: 0.5-0.8 mL.

4. The preparation method according to any one of claims 1 to 3, characterized in that: The irradiation dose is 15 to 30 kGy.

5. Hypoallergenic ovalbumin obtained by the preparation method according to any one of claims 1 to 4.

6. Use of the low-allergenic ovalbumin obtained by the preparation method according to any one of claims 1 to 4 in the preparation of low-allergenic health-care products.

7. Use of the hypoallergenic ovalbumin according to claim 5 in the preparation of hypoallergenic health care products.